ESC Premium Access

Trends in initiation of GLP-1 RA in patients with type 2 diabetes during 2014-2019: a US database study

Presentation

About the speaker

Doctor Mikhail Kosiborod

St. Luke's Mid America Heart Institute, Kansas City (United States of America)
23 presentations
0 follower

57 more presentations in this session

Efficacy of propafenone vs. amiodarone in pharmacological cardioversion of recent-onset atrial fibrillation to sinus rhythm: a pooled meta-analysis of 9 randomized controlled trials

Speaker: Doctor J. Borovac (Split, HR)

Thumbnail

The prevalence and safety of direct oral anticoagulants in patients with non-atrial fibrillation associated intra-cardiac thrombus

Speaker: Doctor A. KANWAL (Valhalla, US)

Thumbnail

Efficiency and safety of the modified protocol for cardioversion of atrial fibrillation using the antiarrhythmic drug niferidil. First results of clinical use.

Speaker: Doctor K. Dzaurova (Moscow, RU)

Thumbnail

The effect of glucagon-like peptide-1 receptor agonists on 24-hour ambulatory blood pressure: a meta-analysis

Speaker: Mrs A. Boulmpou (Thessaloniki, GR)

Thumbnail

Risk of death with sodium-glucose co-transporter-2 inhibitors across the hallmark cardiovascular and renal outcome trials: an updated meta-analysis

Speaker: Mrs A. Boulmpou (Thessaloniki, GR)

Thumbnail

Access the full session

Pharmacology and pharmacotherapy e-posters

Speakers: Doctor M. Kosiborod, Doctor J. Borovac, Doctor A. KANWAL, Doctor K. Dzaurova, Mrs A. Boulmpou...
Thumbnail

About the event

Image

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Related content

ESC Premium Access

SGLT-2 inhibitors in patients with and without a history of heart failure: a meta-analysis

27 August 2021

ESC Premium Access

Cardiovascular outcome in patients treated with SGLT2 inhibitors for heart failure: a meta-analysis

27 August 2021

ESC Premium Access

Distribution of cardiovascular risk in type 2 diabetes: results of an analysis using data from the CAPTURE study

27 August 2021

This platform is supported by

logo Novo Nordisk